NCT00037596View on ClinicalTrials.gov

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2000

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Gemtuzumab Ozogamicin

DRUG

cytarabine.

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00037596 - Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter